Lumos Pharma Q3 EPS $(1.04) Beats $(1.15) Estimate, Sales $7.00K Miss $320.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Lumos Pharma reported Q3 losses of $(1.04) per share, beating the analyst consensus estimate of $(1.15) by 9.57%. However, the company's quarterly sales of $7.00K missed the analyst consensus estimate of $320.00K by 97.81%. This represents a 20.93% decrease in losses and a 98.59% decrease in sales compared to the same period last year.
November 07, 2023 | 10:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lumos Pharma's Q3 earnings beat estimates but sales significantly missed expectations. This could potentially impact investor confidence and the company's stock price.
While Lumos Pharma beat earnings estimates, the significant miss on sales could negatively impact investor sentiment. The decrease in sales compared to the same period last year is also a concerning sign, potentially indicating issues with the company's revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100